Article

Study to evaluate dual AMD therapy

Cleveland-The Cleveland Clinic's Cole Eye Institute will lead a large, multicenter clinical trial to explore combination therapy for wet age-related macular degeneration (AMD).

Cleveland-The Cleveland Clinic's Cole Eye Institute will lead a large, multicenter clinical trial to explore combination therapy for wet age-related macular degeneration (AMD).

The 2-year, randomized, double-masked, controlled multi-center phase IIIb study will assess the safety and efficacy of verteporfin (Visudyne, Novartis Ophthalmics) administered in conjunction with intravitreal ranibizumab (Lucentis, Genentech) in patients with subfoveal choroidal neovascularization (CNV) secondary to wet AMD. The study, which is being called DENALI, will take place at 45 centers in the United States and five in Canada.

"We are exploring the potential to improve outcomes and reduce the frequency of treatments by combining therapies that target different mechanisms responsible for the development of AMD," said Peter Kaiser, MD, the study's lead investigator and an ophthalmologist at Cole Eye Institute.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.